Showing results (41-50 of 162) with videos related to

Sort By:
Pageof 17
Hepatology (Baltimore, Md.)|September 24, 2004
Interleukin 1beta inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearanceEric Assenat, Sabine Gerbal-Chaloin, Dominique Larrey, et al.
Journal of Clinical Lipidology|April 9, 2016
LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and designDirk J Blom, Zahi A Fayad, John J P Kastelein, et al.
Drug Safety|March 18, 2026
Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist ElinzanetantJames H Lewis, Raúl J Andrade, Dominique Larrey, et al.
AIDS (London, England)|August 19, 2004
Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapyStefan Mauss, William Valenti, Jean DePamphilis, et al.
Clinics and Research in Hepatology and Gastroenterology|March 9, 2020
Acute liver failure requiring transplantation caused by ulipristal acetateLucy Meunier, Magdalena Meszaros, Georges-Philippe Pageaux, et al.
International Journal of Cardiology|June 12, 2018
Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent studyLamiae Grimaldi-Bensouda, Heiner Wedemeyer, Johannes Wiegand, et al.
Plos One|May 4, 2019
Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stageSabrina Cossais, Michaël Schwarzinger, Stanislas Pol, et al.
Gastroenterology|April 6, 2007
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonrespondersChristoph Sarrazin, Regine Rouzier, Frank Wagner, et al.
Pharmacoepidemiology and Drug Safety|November 21, 2012
Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in FranceNicholas Moore, Sinem Ezgi Gulmez, Dominique Larrey, et al.
Gut|September 24, 2010
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis CRami Moucari, Nicole Forestier, Dominique Larrey, et al.
Pageof 17